![[OncoHost in PR Newswire] OncoHost Collaborates with BGN Technologies to Predict Cancer Patient Response to Anti-PD-1 Treatment with IcAR Biosensing Tech](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg)
BEER-SHEVA, Israel and BINYAMINA, Israel, Could 4, 2023 /PRNewswire/ — OncoHost, a know-how firm reworking the strategy to precision medication for improved affected person outcomes, right this moment introduced that it has signed an choice settlement with BGN Applied sciences, the know-how switch firm of Ben-Gurion College of the Negev (BGU), to obtain a license for a novel biosensing know-how known as IcAR (Immuno-checkpoint Synthetic Reporter). IcAR was developed by a workforce of researchers from BGU.
Learn extra right here.